JP4846598B2 - 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 - Google Patents
弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 Download PDFInfo
- Publication number
- JP4846598B2 JP4846598B2 JP2006550049A JP2006550049A JP4846598B2 JP 4846598 B2 JP4846598 B2 JP 4846598B2 JP 2006550049 A JP2006550049 A JP 2006550049A JP 2006550049 A JP2006550049 A JP 2006550049A JP 4846598 B2 JP4846598 B2 JP 4846598B2
- Authority
- JP
- Japan
- Prior art keywords
- myxoma virus
- virus
- attenuated
- myxoma
- passages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700562 Myxoma virus Species 0.000 title claims description 124
- 230000002238 attenuated effect Effects 0.000 title claims description 77
- 230000036039 immunity Effects 0.000 title claims description 60
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims description 21
- 239000000411 inducer Substances 0.000 title description 26
- 241000700605 Viruses Species 0.000 claims description 45
- 238000004113 cell culture Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 230000001939 inductive effect Effects 0.000 claims description 29
- 210000003711 chorioallantoic membrane Anatomy 0.000 claims description 28
- 208000009091 myxoma Diseases 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 210000003501 vero cell Anatomy 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 210000000605 viral structure Anatomy 0.000 claims description 19
- 210000000987 immune system Anatomy 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 229960000380 propiolactone Drugs 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 11
- 230000002779 inactivation Effects 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 235000013601 eggs Nutrition 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 210000004779 membrane envelope Anatomy 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 230000006978 adaptation Effects 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 102000003675 cytokine receptors Human genes 0.000 claims description 7
- 108010057085 cytokine receptors Proteins 0.000 claims description 7
- 210000003292 kidney cell Anatomy 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000003054 hormonal effect Effects 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 230000000644 propagated effect Effects 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000013632 homeostatic process Effects 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 206010061308 Neonatal infection Diseases 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 229940124452 immunizing agent Drugs 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 description 38
- 238000002649 immunization Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 244000052769 pathogen Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 14
- 230000007123 defense Effects 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 241000283977 Oryctolagus Species 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 4
- 108090000942 Lactalbumin Proteins 0.000 description 4
- 241000270322 Lepidosauria Species 0.000 description 4
- 208000001203 Smallpox Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 239000007935 oral tablet Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000283986 Lepus Species 0.000 description 3
- 241000283985 Lepus europaeus Species 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008260 defense mechanism Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940096978 oral tablet Drugs 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108010013480 succinylated gelatin Proteins 0.000 description 3
- 229940007079 succinylated gelatin Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000006611 pharmacological activation Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 235000009432 Gossypium hirsutum Nutrition 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000283975 Sylvilagus Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035781 nonspecific defense system Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000035886 specific defense system Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- -1 ttenuated Species 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004003572A DE102004003572A1 (de) | 2004-01-23 | 2004-01-23 | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| DE102004003572.5 | 2004-01-23 | ||
| PCT/EP2005/000582 WO2005070453A1 (de) | 2004-01-23 | 2005-01-21 | Monoparamunitätsinducer basierend auf attenuierten myxomaviren des kaninchens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007534664A JP2007534664A (ja) | 2007-11-29 |
| JP2007534664A5 JP2007534664A5 (enExample) | 2011-02-10 |
| JP4846598B2 true JP4846598B2 (ja) | 2011-12-28 |
Family
ID=34800965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550049A Expired - Fee Related JP4846598B2 (ja) | 2004-01-23 | 2005-01-21 | 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (9) | US7494799B2 (enExample) |
| EP (2) | EP2327420A3 (enExample) |
| JP (1) | JP4846598B2 (enExample) |
| KR (2) | KR20120076396A (enExample) |
| CN (1) | CN1909923B (enExample) |
| AU (1) | AU2005205912B2 (enExample) |
| BR (1) | BRPI0506489A (enExample) |
| CA (1) | CA2547757A1 (enExample) |
| DE (1) | DE102004003572A1 (enExample) |
| EA (1) | EA009937B1 (enExample) |
| IL (1) | IL176634A (enExample) |
| NO (1) | NO20063605L (enExample) |
| NZ (1) | NZ548189A (enExample) |
| UA (1) | UA91501C2 (enExample) |
| WO (1) | WO2005070453A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004003572A1 (de) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| DE102005027956B4 (de) * | 2005-06-16 | 2009-10-22 | Mayr, Anton, Prof. Dr. Dr. h.c. mult. | Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen |
| CN102230035B (zh) * | 2011-07-06 | 2013-02-13 | 中华人民共和国江苏出入境检验检疫局 | 兔粘液瘤病毒pcr检测试剂盒及其应用 |
| JP6370082B2 (ja) * | 2014-04-07 | 2018-08-08 | キヤノン株式会社 | 情報処理装置、情報処理方法、及びプログラム |
| JP2017083973A (ja) * | 2015-10-23 | 2017-05-18 | 富士通株式会社 | 表示端末装置、表示制御方法および表示制御プログラム |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003528925A (ja) * | 2000-04-03 | 2003-09-30 | ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション | 低温適応型ウマインフルエンザウイルス |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| DE4405841C1 (de) | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| EE05633B1 (et) * | 2000-03-14 | 2013-02-15 | Mayr Anton | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| EP1532172A2 (en) | 2002-08-30 | 2005-05-25 | Glaxo Group Limited | Immunogenic composition comprising an il-13 element and t cell epitopes, and itstherapeutic use |
| CA2510309C (en) * | 2002-12-16 | 2014-09-16 | Liyange P. Perera | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| US6960345B2 (en) * | 2003-03-06 | 2005-11-01 | Incell Corporation, Llc | Oral vaccinia formulation |
| CA2517147C (en) * | 2003-03-07 | 2011-06-14 | Robarts Research Institute | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
| DE102004003572A1 (de) | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| DE102005027956B4 (de) * | 2005-06-16 | 2009-10-22 | Mayr, Anton, Prof. Dr. Dr. h.c. mult. | Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen |
-
2004
- 2004-01-23 DE DE102004003572A patent/DE102004003572A1/de not_active Withdrawn
-
2005
- 2005-01-21 BR BRPI0506489-9A patent/BRPI0506489A/pt not_active IP Right Cessation
- 2005-01-21 CA CA002547757A patent/CA2547757A1/en not_active Abandoned
- 2005-01-21 KR KR1020127015730A patent/KR20120076396A/ko not_active Ceased
- 2005-01-21 JP JP2006550049A patent/JP4846598B2/ja not_active Expired - Fee Related
- 2005-01-21 US US10/587,082 patent/US7494799B2/en not_active Expired - Fee Related
- 2005-01-21 NZ NZ548189A patent/NZ548189A/en not_active IP Right Cessation
- 2005-01-21 UA UAA200609278A patent/UA91501C2/ru unknown
- 2005-01-21 WO PCT/EP2005/000582 patent/WO2005070453A1/de not_active Ceased
- 2005-01-21 AU AU2005205912A patent/AU2005205912B2/en not_active Ceased
- 2005-01-21 CN CN2005800030491A patent/CN1909923B/zh not_active Expired - Fee Related
- 2005-01-21 EP EP10014101A patent/EP2327420A3/de not_active Withdrawn
- 2005-01-21 EA EA200601361A patent/EA009937B1/ru not_active IP Right Cessation
- 2005-01-21 EP EP05701103A patent/EP1711204A1/de not_active Withdrawn
-
2006
- 2006-06-16 KR KR1020067011956A patent/KR101209141B1/ko not_active Expired - Fee Related
- 2006-06-29 IL IL176634A patent/IL176634A/en not_active IP Right Cessation
- 2006-08-09 NO NO20063605A patent/NO20063605L/no not_active Application Discontinuation
-
2008
- 2008-02-28 US US12/039,181 patent/US7691391B2/en not_active Expired - Fee Related
- 2008-02-28 US US12/039,120 patent/US7939085B2/en not_active Expired - Fee Related
-
2010
- 2010-08-06 US US12/851,751 patent/US8142796B2/en not_active Expired - Fee Related
- 2010-09-28 US US12/892,186 patent/US8034356B2/en not_active Expired - Fee Related
- 2010-09-28 US US12/892,613 patent/US8039004B2/en not_active Expired - Fee Related
-
2011
- 2011-09-16 US US13/234,269 patent/US20120009217A1/en not_active Abandoned
- 2011-09-16 US US13/234,320 patent/US20120009654A1/en not_active Abandoned
- 2011-11-29 US US13/305,897 patent/US20120070464A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003528925A (ja) * | 2000-04-03 | 2003-09-30 | ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション | 低温適応型ウマインフルエンザウイルス |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100540051C (zh) | 用于接种新生儿的改良的安卡拉痘苗病毒 | |
| TWI711462B (zh) | 二價豬流感病毒疫苗 | |
| US8142796B2 (en) | Monoparamunity inducers based on attenuated rabbit myxomaviruses | |
| JP2007534664A5 (enExample) | ||
| KR20220021304A (ko) | 돼지 써코바이러스 예방용 백신 조성물 | |
| RU2678981C2 (ru) | Композиция от бешенства, содержащая адъювант pika | |
| JP2008546377A (ja) | 高度に弱毒化されたポックスウイルス株、その生産方法および防護免疫誘導剤としての使用またはベクターワクチンを生産するための使用 | |
| HK1095746B (en) | Monoparamunity inducers based on attenuated rabbit myxoma viruses | |
| MXPA06008005A (en) | Monoparaimmunity inducers based on attenuated rabbit myxoma viruses | |
| HK1078777B (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| JP2018008908A (ja) | 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070914 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101125 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101220 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110121 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110121 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110622 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110920 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111012 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |